Risk of recurrent venous thromboembolism and bleeding in patients with interstitial lung disease: a cohort study.
Bleeding
Idiopathic pulmonary fibrosis
Interstitial lung disease
Venous thromboembolism
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
24
06
2021
pubmed:
8
7
2021
medline:
7
4
2022
entrez:
7
7
2021
Statut:
ppublish
Résumé
Interstitial lung disease (ILD) encompasses various parenchymal lung disorders, which has the potential to increase the risk of venous thromboembolism (VTE). To evaluate, in patients with ILD and VTE, the risk of recurrent VTE during follow-up after stopping anticoagulation. This was a cohort of patients with a first VTE recruited between 1997 and 2015. The primary outcome was adjudicated fatal or nonfatal recurrent VTE after stopping anticoagulation. Main secondary outcomes were major or clinically relevant non-major bleeding under anticoagulation. Among 4314 patients with VTE, 50 had ILD diagnosed before VTE. Of these, anticoagulation was stopped in 30 patients after a median duration of 180 days and continued indefinitely in 20 patients. During a median follow-up of 27.8 months after anticoagulation discontinuation, recurrent VTE occurred in 15 on 30 patients (annual incidence of 19.2 events per 100-person-years [95%CI 12.0-29.3], case-fatality rate of 6.7% [95%CI 1.21-29.8]). The risk of recurrence was threefold higher when VTE was unprovoked and case-fatality rate of recurrence was increased by 3 when VTE index was PE. During the anticoagulant period, (median duration of 8.6 months), 6 patients had a major or clinically relevant bleeding (annual incidence of 7.3 events per 100-person-years [95%CI 3.4-15.1], case-fatality rate of 16.7% [95%CI 3.0-56.4]). In patients with ILD, the risk of recurrent VTE after stopping anticoagulation and the risk of bleeding under anticoagulation were very high. Our results suggest that anticoagulation should not be prolonged beyond 3-6 months of anticoagulation in most of cases.
Identifiants
pubmed: 34232453
doi: 10.1007/s11239-021-02518-z
pii: 10.1007/s11239-021-02518-z
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-73Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160(6):761–768
doi: 10.1001/archinte.160.6.761
Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92(2):199–205
doi: 10.3324/haematol.10516
Carrier M, Le Gal G, Wells PS, Rodger MA (2010) Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152(9):578–589
doi: 10.7326/0003-4819-152-9-201005040-00008
Sode BF, Dahl M, Nielsen SF, Nordestgaard BG (2010) Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 181(10):1085–1092
doi: 10.1164/rccm.200912-1951OC
Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748
doi: 10.1164/rccm.201308-1483ST
Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A (1995) Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 77(6):493–504
doi: 10.1016/0049-3848(95)00025-9
Navaratnam V, Fogarty AW, McKeever T, Thompson N, Jenkins G, Johnson SR et al (2014) Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax 69(3):207–215
doi: 10.1136/thoraxjnl-2013-203740
Wygrecka M, Kwapiszewska G, Jablonska E, von Gerlach S, Henneke I, Zakrzewicz D et al (2011) Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(12):1703–1714
doi: 10.1164/rccm.201009-1479OC
Chambers RC (2008) Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 153(Suppl 1):S367-378
doi: 10.1038/sj.bjp.0707603
Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YCG, Kaminski N et al (2009) Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 119(9):2550–2563
pubmed: 19652365
pmcid: 2735922
Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ et al (2012) Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 39(1):125–132
doi: 10.1183/09031936.00041411
Dalleywater W, Powell HA, Fogarty AW, Hubbard RB, Navaratnam V (2014) Venous thromboembolism in people with idiopathic pulmonary fibrosis: a population-based study: Table 1–. Eur Respir J 44(6):1714–1715
doi: 10.1183/09031936.00099614
Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW (2008) The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 178(12):1257–1261
doi: 10.1164/rccm.200805-725OC
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352
doi: 10.1016/j.chest.2015.11.026
Konstantinides S (2008) Clinical practice. Acute pulmonary embolism. N Engl J Med 359(26):2804–13
doi: 10.1056/NEJMcp0804570
Kearon C, Julian JA, Newman TE, Ginsberg JS (1998) Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 128(8):663–77
doi: 10.7326/0003-4819-128-8-199804150-00011
PIOPED Investigators (1990) Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 263(20):2753–2759
Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W et al (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost JTH 8(1):202–204
doi: 10.1111/j.1538-7836.2009.03678.x
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost JTH 3(4):692–694
Hansson PO, Sörbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 160(6):769–774
doi: 10.1001/archinte.160.6.769
Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125(1):1–7
doi: 10.7326/0003-4819-125-1-199607010-00001
Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E et al (2015) Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE Randomized Clinical Trial. JAMA 314(1):31–40
doi: 10.1001/jama.2015.7046
Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349(7):631–639
doi: 10.1056/NEJMoa035422
Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J et al (2011) Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 342:d3036
doi: 10.1136/bmj.d3036
Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105(2):91–99
doi: 10.1016/S0002-9343(98)00198-3
Beyth RJ, Quinn L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 133(9):687–95
doi: 10.7326/0003-4819-133-9-200011070-00010
Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M et al (2005) Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128(3):1475–1482
doi: 10.1378/chest.128.3.1475
King TE, Pardo A, Selman M (2011) Idiopathic pulmonary fibrosis. Lancet Lond Engl 378(9807):1949–1961
doi: 10.1016/S0140-6736(11)60052-4
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. The Lancet 377(9779):1760–1769
doi: 10.1016/S0140-6736(11)60405-4
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C et al (2012) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186(1):88–95
doi: 10.1164/rccm.201202-0314OC
Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U et al (2016) Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 47(6):1776–1784
doi: 10.1183/13993003.02087-2015
Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D et al (2015) Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 46(1):186–196
doi: 10.1183/09031936.00217614
Kraaijpoel N, Tritschler T, Guillo E, Girard P, Le Gal G (2019) Definitions, adjudication, and reporting of pulmonary embolism-related death in clinical studies: a systematic review. J Thromb Haemost 17(10):1590–1607
doi: 10.1111/jth.14570